Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y

Core Insights - Perrigo Company plc (PRGO) reported adjusted earnings of 93 cents per share in Q4 2024, surpassing the Zacks Consensus Estimate of 92 cents, marking an 8% year-over-year increase due to improved margins and lower variable expenses [1] - Net sales for the quarter declined 1.6% year over year to $1.14 billion, falling short of the Zacks Consensus Estimate of$1.20 billion, primarily due to lost sales from exited businesses and product lines [1][2] - For the full year 2024, Perrigo's revenues totaled $4.37 billion, a decrease of 6.1$2.57 per share, down 0.4% from the previous year [7] Sales Performance - In the Consumer Self Care Americas (CSCA) segment, net sales were flat year over year at 744 million, with growth in Nutrition, Skin Care, and Women's Health categories offset by declines in Pain & Sleep Aids, Upper Respiratory, and Digestive Health categories [5] - The Consumer Self Care International (CSCI) segment reported net sales of 394 million, down 4.5% year over year due to product line exits and unfavorable currency movements, although organic sales increased by 1.8% [6] Future Outlook - Perrigo is set to host a virtual Investor Day to present its strategic plan for 2025-2027 and provide financial guidance for the full year 2025 [8]